All‐cause mortality · patients with chronic obstructive pulmonary disease
Self‐management interventions showed no clear difference in all‐cause mortality compared with usual care (low certainty).
Mortality (all‐cause) · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether remote monitoring plus usual care changes mortality (all‐cause) compared with usual care (very low certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether remote monitoring changes mortality (all‐cause) compared with usual care (very low certainty).
1 finding from 1 review
All‐cause mortality · Adults with COPD
Statins showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes mortality (all‐cause) compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Mortality (all‐cause) · acute exacerbations of chronic obstructive pulmonary disease
Action plan showed no clear difference in mortality (all‐cause) compared with usual care (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in mortality (all‐cause) compared with tiotropium (moderate certainty).
1 finding from 1 review
Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with long‐acting beta2‐agonist alone (low certainty).
1 finding from 1 review
Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with tiotropium alone (low certainty).
1 finding from 1 review
Mortality (all‐cause) · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium showed no clear difference in mortality (all‐cause) compared with ipratropium (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality, all‐cause · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in mortality, all‐cause (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality, all‐cause · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in mortality, all‐cause (high certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in mortality (all‐cause) compared with placebo (low certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history
It is very uncertain whether tiotropium changes mortality (all‐cause) compared with long‐acting beta‐agonists (very low certainty).
1 finding from 1 review